Genetic Medicine:

Page 11234..1020..»

Psoriasis Overview – Mayo Clinic

In psoriasis, the life cycle of your skin cells greatly accelerates, leading to a buildup of dead cells on the surface of the epidermis.

Psoriasis is a common skin condition that speeds up the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form scales and red patches that are itchy and sometimes painful.

Psoriasis is a chronic disease that often comes and goes. The main goal of treatment is to stop the skin cells from growing so quickly.

There is no cure for psoriasis, but you can manage symptoms. Lifestyle measures, such as moisturizing, quitting smoking and managing stress, may help.

Psoriasis care at Mayo Clinic

Read more here:
Psoriasis Overview – Mayo Clinic

Read the Rest...

‘Scandal’ actress Katie Lowes opens up about psoriasis – WATE 6 On Your Side

KNOXVILLE (WATE) Quinn Perkins, played by Actress Katie Lowes is one tough cookie on the show Scandal, but she is also tough in real life.

Lowes has lived with a chronic autoimmune disease known as psoriasis for the past eight years. She says she was diagnosed with psoriasis eight years ago but finally decided to go public with her experiences in the hopes of helping others.

When I was first diagnosed I was so embarrassed and ashamed. You know, being an actress in Hollywood, there is such a pressure to look a certain way and after living with it for eight years, says Lowes, Im really living my best life and I thought there are 7.5 million other Americans living with this disease and if I can help even one of them feel inspired to be there own best advocate to get to a place where they are living their fullest life and theyre not limiting themselves because of psoriasis, then that would just be a huge win.

The actress is partnering with Jansen and the National Psoriasis Foundation on a campaign called Inside Story. She shares her story about living with psoriasis and encourages others to do the same.

While on the set of Scandal, Lowes said there were times when she had flare-ups. She said there were times when she couldnt wear a certain red carpet look or wear a bathing suit on vacation.

There are all these limitations placed on your life and I know from personal experience it can be so upsetting and you can feel so alone, but with 7.5 million people living with this disease, you are not, said Lowes. This site is a wonderful tool that people struggling with psoriasis can use to their benefit because I want people to feel, you know, that we are a large community that we support each other. I want to encourage people to find a doctor they can trust, to find a treatment that works for them and I just want people to know that it is possible to get to a place where youre not limiting fashion and style and being with our family and things like that.

Lowes appears on the final season of Scandal which airs Thursdays on WATE 6 On Your Side. When asked if she knows how the show will end, Lowes said she is under lock-and-key.

We are not allowed to say anything, but I can assure you that this will be the final season of Scandal and the writers are leaving it all on the dance floor and it is going to be a wild and crazy ride for sure.

Excerpt from:
‘Scandal’ actress Katie Lowes opens up about psoriasis – WATE 6 On Your Side

Read the Rest...

Adalimumab Safe and Effective Therapy for Pediatric Psoriasis – Medical News Bulletin

As an inhibitor of an inflammatory protein associated with the development of psoriasis, adalimumab shows promise as a therapy for pediatric patients with severe plaque psoriasis. Adalimumab treatment for 16 weeks in children and adolescents with severe plaque psoriasis provides significant improvements compared to methotrexate.

Psoriasis is a chronic skin condition characterized by scales and red patches that are typically found on the scalp, elbows, and knees. This buildup of extra skin cells on the surface of the epidermis is an autoimmune inflammatory disease, which is currently incurable. Immune system T-cells and an abundance of inflammatory protein tumor necrosis factor-alpha (TNF-) play major roles in the development of psoriasis. Though there are many types of psoriasis, plaque psoriasis is the most common condition which involves the build-up of plaque on the surface of the skin. Itching, burning, soreness, or cracked skin are some of the symptoms associated with the disease and its severity can be classified as mild, affecting less than 5% of the skins surface area, moderate, affecting 5 to 10% of the skin, or severe, with more than 10% of the skins surface affected. Affecting 2% of the general population, a third of psoriasis diagnoses made by physicians include those who are 20 years of age and younger.

Management of pediatric psoriasis can decrease the risk of psychosocial issues and comorbidities such as, hypertension and diabetes. Initial treatment for patients with limited disease includes topical therapies, while severe pediatric psoriasis is treated using ultraviolet B phototherapy, or systemic treatments, such as methotrexate, ciclosporin, or retinoids. However, though TNF- inhibitor, methotrexate, has been prescribed to treat children and adolescents, it has not been approved by the European Medicine Agency, thus making it a good candidate for clinical research assessment. Due to the lack of standardized guidelines and approved systemic therapies, managing psoriasis by the blockage of TNF-, has been challenging. However, in 2015, TNF- inhibitor, adalimumab, was approved in the United States to treat severe cases in patients who were 4 years of age and older, and who did not respond adequately to topical therapy or phototherapies. Therefore, it is important to compare both inhibitors for their safety and efficacy in treating severe pediatric plaque psoriasis.

A double-blind randomized controlled study was performed to compare the safety and efficacy of adalimumab and methotrexate in children with severe psoriasis. Treatment groups consisted of a total of 114 patients who were randomly assigned to receive either 0.8 mg/kg of adalimumab, 0.4 mg/kg of adalimumab, or 0.1-0.4 mg/kg of methotrexate. Adalimumab was given subcutaneously every other week, whereas, methotrexate was taken orally once weekly. The study consisted of four periods; identified as the 16-week primary treatment, up to 36-week withdrawal, 16-week re-treatment, and 52-week long-term follow-up. Measurements based on the Psoriasis Area and Severity Index (PASI) assessed the percentage of skin affected and 75% improvement, PASI75, was a study endpoint. The Physician Global Assessment (PGA), which measures psoriasis activity, was used to identify clear or minimal areas. At week 16, PASI75 was achieved in 58% of the patients receiving 0.8mg/kg of adalimumab, in 44% of patients receiving 0.4 mg/kg of adalimumab, and in 32% of patients taking methotrexate. Results from the PGA showed 61% of patients receiving 0.8mg/kg of adalimumab, 41% of patients receiving 0.4 mg/kg adalimumab, and 41% of patients taking methotrexate had a clear or minimal PGA score. Initial treatments resulted in adverse events, such as infections for 45% of the patients receiving 0.8 mg/kg of adalimumab, in 56% of the patients receiving 0.4 mg/kg of adalimumab, and in 51% of those taking methotrexate. Compared to methotrexate, treatment with adalimumab in children and adolescents with severe plaque psoriasis provided significant improvements in PASI75. Although there was an increase in the number of patients with a clear or minimal PGA score in the adalimumab group compared to methotrexate, these results did not reach statistical significance. Overall, adalimumab was found to be more effective than methotrexate, with a rapid response and similar safety profile after 16 weeks.

This study is one of few investigations that characterize the long-term safety of treatment of severe psoriasis in children. Though a limitation of the study was a lack of methotrexate control data to compare to the investigated population, the safety and efficacy profile of adalimumab was successfully evaluated for comparison to methotrexate. In conclusion, treatment with 0.8 mg/kg of adalimumab for 16 weeks in children and adolescents with severe plaque psoriasis provided significant improvements in PASI75 and a non-significant increase in patients who achieved clear or minimal PGA compared with methotrexate. These findings provide new insight and an additional option for safe and effective therapy of severe plaque psoriasis in a young population.

Written By:Viola Lanier, Ph. D., M. Sc.

Add to Flipboard Magazine.

Follow this link:
Adalimumab Safe and Effective Therapy for Pediatric Psoriasis – Medical News Bulletin

Read the Rest...

Dara Torres Is ‘Ready to Talk’ to Her Daughter About Body Confidence After Managing Psoriasis and an Eating Disorder –

Between overcoming an eating disorder in college and managing her psoriasis for the last 25 years, swimmer Dara Torres is fully prepared for any body image conversations her 11-year-old daughter Tessathrows her way.

The 12-time Olympic medalist says the questionshave already started.

She has talked to me actually a few weeks ago about body confidence, because she had to go to an end of the year school party and it was a pool party, and she wanted to talk to me about her body and what swimsuits to wear and having confidence, Torres, 50, tells PEOPLE. And it was the first time she ever really approached me about that on her own. So I was proud of her for being open about that.

Torres says her own background made it easier to relate.

I think the fact that I had an eating disorder in college, and then developing plaque psoriasis, I definitely had some confidence issues and self-esteem issues, she says. So I definitely am completely educated and ready to talk to her about any body image questions she has.

RELATED VIDEO:9 Celebrities Who Struggle with Psoriasis

Dealing with her plaque psoriasis as a young swimmer Torres first noticed the itchy, red rashes as a 25-year-old during the run up to the 1992 Barcelona Games was tough at first.

I was really embarrassed by it, because my business suit is a swimsuit. I needed to be on the pool deck in a little Speedo with these red patches all over me, Torres says.

But gaining the confidence to ignore her psoriasis was key to managing it, particularly because Torres is triggered by stress. Now she works to share that strength with other psoriasis sufferers by working withOtezla and Celgene on their Show More of You campaign.

I want to get the word out that you can have confidence and you can follow your dreams, Torres says. You can be yourself and not worry about what other people think.

Go here to read the rest:
Dara Torres Is ‘Ready to Talk’ to Her Daughter About Body Confidence After Managing Psoriasis and an Eating Disorder –

Read the Rest...

Page 11234..1020..»